Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study

BACKGROUND: This multicenter phase II study investigated temozolomide + irinotecan (TEMIRI) treatment in children with relapsed or refractory medulloblastoma. METHODS: Patients received temozolomide 100–125 mg/m(2)/day (days 1–5) and irinotecan 10 mg/m(2)/day (days 1–5 and 8–12) every 3 weeks. The p...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Grill, Jacques, Geoerger, Birgit, Gesner, Lyle, Perek, Danuta, Leblond, Pierre, Cañete, Adela, Aerts, Isabelle, Madero, Luis, de Toledo Codina, Josep Sanchez, Verlooy, Joris, Estlin, Edward, Cisar, Laura, Breazna, Aurora, Dorman, Andrew, Bailey, Simon, Nicolin, Gary, Grundy, Richard G., Hargrave, Darren
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2013
Konular:
Clinical Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3748925/
https://ncbi.nlm.nih.gov/pubmed/23857707
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not097
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller